OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press18010.17650/1818-8346-2016-11-1-37-46HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯAnemia of chronic diseases: the important aspects of pathogenesis and treatmentАнемия хронических заболеваний: отдельные аспекты патогенеза и пути коррекцииRukavitsynO. A.РукавицынО. А.
Russian Federation
ngc@list.ruN. N. Burdenko Main Military Clinical Hospital, Ministry of Defence of RussiaФГКУ «Главный военный клинический госпиталь им акад. Н. Н. Бурденко» Минобороны России3 Gospital’naya Square, Moscow, 105229, RussiaРоссия, 105229, Москва, Госпитальная площадь, 3ru31032016201611137463103201631032016Received:31032016Accepted:31032016Published:31032016https://oncohematology.abvpress.ru/ongm/article/view/180

The review contains data about new important aspects of pathogenesis, and treatment of anemia of chronic diseases. The treatment of patients with anemia of chronic diseases by erythropoiesis-stimulating agents and iron is analyzed.

В обзоре приведены данные, касающиеся новых важных аспектов патогенеза и лечения анемии хронических заболеваний. Показана роль эритропоэз-стимулирующих агентов и препаратов железа в лечении пациентов с анемией хронических заболеваний.

anemia of chronic diseasesironerythropoiesis-stimulating agentsанемия хронических заболеванийжелезоэритропоэз-стимулирующие агенты1. Вуд М. Э., Банн П. А. Секреты гематологии и онкологии. М.: Бином, 1997. 560 с. [Vud M. E., Bann P. A. Secrets of hematology and oncology. Moscow: Binom, 1997. 560 p. (In Russ.)].Вуд М. Э., Банн П. А. Секреты гематологии и онкологии. М.: Бином, 1997. 560 с. [Vud M. E., Bann P. A. Secrets of hematology and oncology. Moscow: Binom, 1997. 560 p. (In Russ.)].2. Руководство по гематологии. Под ред. А. И. Воробьева. Т. 3. М.: Ньюдиамед, 2005. 415 с. [Hematology guide. Ed. by A. I. Vorob’ev. Vol. 3. Moscow: Newdiamed, 2005. 415 p. (In Russ.)].Руководство по гематологии. Под ред. А. И. Воробьева. Т. 3. М.: Ньюдиамед, 2005. 415 с. [Hematology guide. Ed. by A. I. Vorob’ev. Vol. 3. Moscow: Newdiamed, 2005. 415 p. (In Russ.)].3. Новик А. А., Богданов А. Н. Анемия (от А до Я). Руководство для врачей. СПб.: Нева, 2004. 250 с. [Novik A. A., Bogdanov A. N. Anemia (A to Z). Medical guidelines. St. Petersburg: Neva, 2004. 250 p. (In Russ.)].Новик А. А., Богданов А. Н. Анемия (от А до Я). Руководство для врачей. СПб.: Нева, 2004. 250 с. [Novik A. A., Bogdanov A. N. Anemia (A to Z). Medical guidelines. St. Petersburg: Neva, 2004. 250 p. (In Russ.)].4. Болезни крови пожилых. Под ред. М. Дж. Дэнхэма, И. Чанарина. М.: Медицина, 1989. 480 с. [Blood disorders in the elderly. Ed. by M. J. Denhem, I. Chanarin. Moscow: Meditsina, 1989. 480 p. (In Russ.)].Болезни крови пожилых. Под ред. М. Дж. Дэнхэма, И. Чанарина. М.: Медицина, 1989. 480 с. [Blood disorders in the elderly. Ed. by M. J. Denhem, I. Chanarin. Moscow: Meditsina, 1989. 480 p. (In Russ.)].5. Павлов А. Д., Морщакова Е. Ф., Румянцев А. Г. Эритропоэз, эритропоэтин, железо. М.: ГЭОТАР-медиа, 2011. 299 с. [Pavlov A. D., Morshchakova E. F., Rumyantsev A. G. Erythropoiesis, erythropoietin, iron. Moscow: GEOTAR-media, 2011. 299 p. (In Russ.)].Павлов А. Д., Морщакова Е. Ф., Румянцев А. Г. Эритропоэз, эритропоэтин, железо. М.: ГЭОТАР-медиа, 2011. 299 с. [Pavlov A. D., Morshchakova E. F., Rumyantsev A. G. Erythropoiesis, erythropoietin, iron. Moscow: GEOTAR-media, 2011. 299 p. (In Russ.)].6. Шиффман Ф. Дж. Патофизиология крови. М.: Бином; СПб.: Невский диалект, 2000. 451 с. [Shiffman F. J. Blood pathophysiology. Moscow: Binom; St. Petersburg: Nevskiy dialekt, 2000. 451 p. (In Russ.)].Шиффман Ф. Дж. Патофизиология крови. М.: Бином; СПб.: Невский диалект, 2000. 451 с. [Shiffman F. J. Blood pathophysiology. Moscow: Binom; St. Petersburg: Nevskiy dialekt, 2000. 451 p. (In Russ.)].7. Cartwright G. E., Wintrobe M. M. The anemia of infection: a review. Adv Intern Med 1952;5:165–226.Cartwright G. E., Wintrobe M. M. The anemia of infection: a review. Adv Intern Med 1952;5:165–226.8. Arezes J., Nemeth E. Hepsidin and iron disorders: new biology and clinical approaches. Int J Lab Hematol 2015;37 Suppl 1:92–8.Arezes J., Nemeth E. Hepsidin and iron disorders: new biology and clinical approaches. Int J Lab Hematol 2015;37 Suppl 1:92–8.9. Jurado R. L. Iron, infections, and anemia of inflammation. Clin Infect Dis 1997;25(4):888–95.Jurado R. L. Iron, infections, and anemia of inflammation. Clin Infect Dis 1997;25(4):888–95.10. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102(3):783–8.Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102(3):783–8.11. Nicolas G., Bennoun M., Porteu A. et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002;99(7):4596–601.Nicolas G., Bennoun M., Porteu A. et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002;99(7):4596–601.12. Andrews N. С. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004;113(9):1251–3.Andrews N. С. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004;113(9):1251–3.13. Park S., Jung C. W., Kim K. et al. Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. 2015;6(40):42803–12.Park S., Jung C. W., Kim K. et al. Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. 2015;6(40):42803–12.14. Ludwig H., Fritz E., Leitgeb C. et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994;84(4):1056–63.Ludwig H., Fritz E., Leitgeb C. et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994;84(4):1056–63.15. Schilling R. F. Anemia of chronic disease: a misnomer. Ann Intern Med 1991;115(7):572–3.Schilling R. F. Anemia of chronic disease: a misnomer. Ann Intern Med 1991;115(7):572–3.16. Weiss G., Goodnough L. T. Anemia of chronic disease. N Engl J Med 2005;352(10):1011–23.Weiss G., Goodnough L. T. Anemia of chronic disease. N Engl J Med 2005;352(10):1011–23.17. Wilson A., Reyes E., Ofinan J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004; 116 Suppl 7A:44S–9S.Wilson A., Reyes E., Ofinan J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004; 116 Suppl 7A:44S–9S.18. Steinmets T., Tschechne B., Harlin O. et al. Clinical experience with ferric carboximaltose in treatment of cancer- and chemotherapy-associated anemia. Ann Oncol 2013;24(2):475–82.Steinmets T., Tschechne B., Harlin O. et al. Clinical experience with ferric carboximaltose in treatment of cancer- and chemotherapy-associated anemia. Ann Oncol 2013;24(2):475–82.19. Maury C. P., Liljestrom M., Laiho K. et al. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 2003;48(11):3068–70.Maury C. P., Liljestrom M., Laiho K. et al. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 2003;48(11):3068–70.20. Brissot P., Ropert M., Lee L. C., Loreal O. Non-transferrin bound iron: a key role in iron overload and iron toxisity. Biochim Biophis Acta 2012;1820(3):403–10.Brissot P., Ropert M., Lee L. C., Loreal O. Non-transferrin bound iron: a key role in iron overload and iron toxisity. Biochim Biophis Acta 2012;1820(3):403–10.21. Tarantino G., Brilli E., Giordano G., Torelli A. Innovative oral iron supplement (sucrosomial iron) is able to downregulate hepsidin release during inflammation: in vitro study. Blood 2015;126:4563–5.Tarantino G., Brilli E., Giordano G., Torelli A. Innovative oral iron supplement (sucrosomial iron) is able to downregulate hepsidin release during inflammation: in vitro study. Blood 2015;126:4563–5.22. Rizzo J. D., Brouwers M., Hurley P. et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use epoetin and darbepoetin in adult patients with cancer. Blood 2010;116(20):4045–59.Rizzo J. D., Brouwers M., Hurley P. et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use epoetin and darbepoetin in adult patients with cancer. Blood 2010;116(20):4045–59.23. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 2001;16 Suppl 7: 36–40.Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 2001;16 Suppl 7: 36–40.24. Дрозд М. В., Ермолин В. В., Рукавицын О. А. и др. Болевой синдром (оссалгии) на фоне применения стимуляторов эритропоэза: случайность или побочный эффект? В сб.: Тезисы Всероссийской юбилейной конференции ГВКГ им. Н. Н. Бурденко. М., 2010. С. 207–8. [Drozd M. V., Ermolin V. V., Rukavitsyn O. A. et al. Pain (ossalgia) during treatment with erythropoiesis stimulants: a coincidence or a side effect? In: Abstract book of Russian Anniversary Conference f N. N. Burdenko Main Military Clinical Hospital. Moscow, 2010. Pp. 207–8. (In Russ.)].Дрозд М. В., Ермолин В. В., Рукавицын О. А. и др. Болевой синдром (оссалгии) на фоне применения стимуляторов эритропоэза: случайность или побочный эффект? В сб.: Тезисы Всероссийской юбилейной конференции ГВКГ им. Н. Н. Бурденко. М., 2010. С. 207–8. [Drozd M. V., Ermolin V. V., Rukavitsyn O. A. et al. Pain (ossalgia) during treatment with erythropoiesis stimulants: a coincidence or a side effect? In: Abstract book of Russian Anniversary Conference f N. N. Burdenko Main Military Clinical Hospital. Moscow, 2010. Pp. 207–8. (In Russ.)].25. Bohlius J., Schmidlin K., Brillant C. et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet 2009;373(9674):1532–42.Bohlius J., Schmidlin K., Brillant C. et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet 2009;373(9674):1532–42.26. Glaspy J., Crowford J., Vansteenkiste J. et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102(2):301–15.Glaspy J., Crowford J., Vansteenkiste J. et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102(2):301–15.27. Tsuboi M., Ezaki K., Tobinai K. et al. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of multicenter, phase III, randomized, double-blind, placebo-controlled study. Jpn J Clin Oncol 2009;39(3):163–8.Tsuboi M., Ezaki K., Tobinai K. et al. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of multicenter, phase III, randomized, double-blind, placebo-controlled study. Jpn J Clin Oncol 2009;39(3):163–8.28. Levine M. N., Lee A. Y., Kakkar A. K. Thrombosis and cancer. Am Soc Clin Oncol Ed Book. 2005. Pp. 748–57.Levine M. N., Lee A. Y., Kakkar A. K. Thrombosis and cancer. Am Soc Clin Oncol Ed Book. 2005. Pp. 748–57.29. Дрозд М. В. Анемия у пациентов с лимфопролиферативными заболеваниями: патогенетические особенности и возможности терапии. Автореф. дис. … канд. мед. наук. М., 2007. [Drozd M. V. Anemia in patients with lymphoproliferative diseases: pathogenetic features and therapy options. Author’s abstract of thesis … of candidate of medicine. Moscow, 2007. (In Russ.)].Дрозд М. В. Анемия у пациентов с лимфопролиферативными заболеваниями: патогенетические особенности и возможности терапии. Автореф. дис. … канд. мед. наук. М., 2007. [Drozd M. V. Anemia in patients with lymphoproliferative diseases: pathogenetic features and therapy options. Author’s abstract of thesis … of candidate of medicine. Moscow, 2007. (In Russ.)].30. Aul C., Bowen D. T., Yoshida Y. Pathogenesis, ethiology and epidemiology of myelodysplastic syndromes. Hematologica 1998;83(1):71–86.Aul C., Bowen D. T., Yoshida Y. Pathogenesis, ethiology and epidemiology of myelodysplastic syndromes. Hematologica 1998;83(1):71–86.31. Geary C. C., Marsh J. C., Gordon-Smith E. C. Hypoplastic myelodysplasia (MDS). Br J Haematol 1996;94(3):579–84.Geary C. C., Marsh J. C., Gordon-Smith E. C. Hypoplastic myelodysplasia (MDS). Br J Haematol 1996;94(3):579–84.32. Rarcharidou A., Raza A., Economopoulos T. Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes. Eur J Haematol 1999;62(1):19–26.Rarcharidou A., Raza A., Economopoulos T. Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes. Eur J Haematol 1999;62(1):19–26.33. Ross S. D., Allen I. E., Probst C. A. et al. Efficacy and safety of erythropoiesisstimulating proteins in myelodysplastic syndrome: a systematic review and metaanalysis. Oncologist 2007;12(10):1264–73.Ross S. D., Allen I. E., Probst C. A. et al. Efficacy and safety of erythropoiesisstimulating proteins in myelodysplastic syndrome: a systematic review and metaanalysis. Oncologist 2007;12(10):1264–73.